

## ASX Announcement I 23 January 2024 Althea Group Holdings (ASX:AGH)

# Althea launches range of THC softgel capsules

# Althea is the first supplier of full-spectrum cannabis THC softgel capsules globally

## Highlights:

- Althea is proud to add to its range of innovative softgel capsules with the launch of Althea CBD3:THC2 (3 mg cannabidiol [CBD], 2.5 mg delta-9-tetrahydrocannabinol [THC]) and Althea THC10 (10 mg THC, <0.5 mg CBD)
- The launch of these two products completes the full portfolio of softgel capsules across Althea's three core market segments; CBD-dominant, balanced, and THC-dominant medicines
- Althea anticipates a positive uptake of the balanced and THC-dominant softgel capsules following the successful launch of Althea CBD25 softgel capsules

23 January 2024: Althea Group Holdings Limited (ASX:AGH) ('AGH', or 'the Company'), a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products, is pleased to announce the extension of its softgel capsule product range, with the launch of Althea CBD3:THC2 and Althea THC10.

# Althea CBD3:THC2 and Althea THC10 softgel capsules

The innovative range of Althea softgel capsules offers a fixed-dose, oral formulation providing gradual onset and extended duration of effect. This may be preferred by doctors for the management of chronic conditions such as anxiety, pain, and sleep difficulties, where medicinal cannabis is most commonly prescribed.

Each capsule of Althea CBD3:THC2 contains 3 mg of CBD and 2.5 mg of THC. Each capsule of Althea THC10 contains 10 mg of THC and <0.5 mg CBD.

### Why launch softgel capsules?

Softgel capsules offer a fixed-dose formulation and provide consistent dosing in a familiar and convenient format, supporting overall compliance for patients, which may result in even greater patient retention.

Approximately 300 doctors prescribed Althea CBD25 softgel capsules between March and November 2023, of which ~30% had never prescribed medicinal cannabis before, demonstrating the preference and acceptability of the Althea softgel capsule range. The launch of Althea's THC-based softgel capsules will continue to position Althea as a leader and innovator in the global medicinal cannabis industry.

AGH CEO and Managing Director, Joshua Fegan said: "Althea is pleased to expand its range of softgel capsules to patients with the launch of our balanced (Althea CBD3:THC2) and THC-dominant (Althea THC10) softgel capsules. The successful launch of Althea CBD25 softgel capsules proves that this is the preparation of choice for new and existing prescribers of cannabis-based medicines. We are proud to be the first company globally to offer a portfolio of CBD-dominant, balanced, and THC-dominant, EU-GMP, full-spectrum cannabis softgel capsules."

-ENDS-Althea CONCIERGE

Althea Group Holdings Limited | ABN 78 626 966 943 Level 50, 360 Elizabeth Street, Melbourne 3000, Victoria Australia E info@altheagroupholdings.com

P 1300 70 20 20 w altheagroupholdings.com



Authorised by: Robert Meissner, Company Secretary

### For further information, please contact:

Althea Group Holdings Ltd Joshua Fegan CEO & Managing Director M: 1300 70 20 20 E: contact@althea.life Media & Investor Enquiries Media & Investor Relations P: +613 9650 5096 E: investors@althea.life

#### Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products purchased by adult consumers in retail stores.

AGH operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more about Althea Group Holdings, please visit: www.altheagroupholdings.com

For more information on Peak, please visit: www.peakprocessing.com

For more information on Althea, please visit: www.althea.life







Althea Group Holdings Limited | ABN 78 626 966 943 Level 50, 360 Elizabeth Street, Melbourne 3000, Victoria Australia E info@altheagroupholdings.com